{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:32:19Z","timestamp":1773063139332,"version":"3.50.1"},"reference-count":18,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2015,10,15]]},"abstract":"<jats:p>Hyper-IgD syndrome (HIDS) is a rare, severe hereditary autoinflammatory disease characterised by periodic fevers, elevated serum IgD levels and a wide range of symptoms. Although a few randomised controlled trials have been performed in this disorder, there are no straightforward treatment protocols and none of the potential therapies are registered for this indication. We report a case of a young woman with severe HIDS who failed numerous therapies. Eventually, rational treatment with a monoclonal anti-interleukin 6 receptor antibody was initiated. This therapy resulted in an impressive clinical improvement and reduction in the number of hospital admissions per year. This case report underlines the difficulty of finding a suitable treatment for rare, severe inflammatory diseases. Furthermore, we show that treating patients with targeted therapies may result in clinical benefit for the patient, as well as simultaneously teach us more about the pathophysiology of these rare, relatively understudied diseases.<\/jats:p>","DOI":"10.1136\/bcr-2015-210513","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T12:37:27Z","timestamp":1446122247000},"page":"bcr2015210513","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Anti-interleukin 6 receptor therapy for hyper-IgD syndrome"],"prefix":"10.1136","volume":"2015","author":[{"given":"Anne","family":"Musters","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Academic Medical Center\/University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Peter","family":"Tak","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Academic Medical Center\/University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique L P","family":"Baeten","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Academic Medical Center\/University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander W","family":"Tas","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Academic Medical Center\/University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,10,29]]},"reference":[{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.01.012"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.2","first-page":"260","article-title":"Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model","volume":"63","author":"Bodar","year":"2005","journal-title":"Neth J Med"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-2015"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-006-0164-x"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10545-006-0408-7","article-title":"Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis","volume":"29","author":"Cailliez","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201268"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92505-4"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.8","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s00018-003-2296-4","article-title":"Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation","volume":"60","author":"Houten","year":"2003","journal-title":"Cell Mol Life Sci"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.01.006"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4049\/jimmunol.157.1.400","article-title":"Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of c-reactive protein and serum amyloid in Hep3B cells","volume":"157","author":"Drenth","year":"1996","journal-title":"J Immunol"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.11","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1182\/blood.V85.12.3586.bloodjournal85123586","article-title":"Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome","volume":"85","author":"Drenth","year":"1995","journal-title":"Blood"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.12","first-page":"73","article-title":"TNF-alpha and IL-6 induce differentiation in the human basophilic leukaemia cell line KU812","volume":"81","author":"Nilsson","year":"1994","journal-title":"Immunology"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.13","first-page":"255","article-title":"Immunoglobulin D enhances interleukin-6 release from the KU812 human prebasophil cell line","volume":"22","author":"Sechet","year":"2003","journal-title":"Gen Physiol Biophys"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.14","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1748"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu341"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.16","doi-asserted-by":"publisher","DOI":"10.1097\/01.RHU.0000442576.41537.de"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.17","doi-asserted-by":"publisher","DOI":"10.1177\/1740774510386390"},{"key":"2025082802542751000_2015.oct29_1.bcr2015210513.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.125526"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2015-210513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:54:35Z","timestamp":1756374875000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2015-210513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,29]]},"references-count":18,"alternative-id":["10.1136\/bcr-2015-210513"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2015-210513","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,29]]}}}